|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Operating expenses: | |||||
| Research and development | |||||
| General and administrative | |||||
| Total operating expenses | |||||
| Loss from operations | |||||
| Other income, net | |||||
| Change in fair value of convertible promissory notes | |||||
| Net loss | |||||
| Net loss available to common stockholders per share of common stock, basic | |||||
| Net loss available to common stockholders per share of common stock, diluted | |||||
| Weighted average number of shares used in calculating net loss per share, basic | |||||
| Weighted average number of shares used in calculating net loss per share, diluted | |||||
| Reclassification adjustment for interest earned on marketable securities included in net loss | |||||
| Change in unrealized gain on marketable securities | |||||
| Comprehensive loss | |||||
Loading...